Endocrine Function and Glucose Metabolism in Patients with Parkinson's Disease and their Alteration by l-Dopa1
The DOI matches its Crossref record.
Abstract
The present study was designed to determine if l-dopa alters endocrine function in humans. Patients with Parkinson's disease underwent control studies that included determination of basal 24 hr urinary 17-hydroxy and keto steroids and their response to metyrapone, urinary gonadotropins, serum thyroxine, 24 hr 131I uptake by thyroid gland and the plasma glucose, insulin and growth hormone responses to oral glucose, iv glucose, iv tolbutamide and iv insulin. During the third week of l-dopa therapy (6.0 g/day) the studies were repeated. l-dopa had no effect on thyroid or adrenal function. Metyrapone response and urinary excretion of gonadotropins were unaltered. Glucose decay constants and insulin secretion following the iv glucose and tolbutamide were not changed. The oral glucose tolerance was modified in that early insulin secretion (0 to 120 min) was significantly inhibited (60.6% of control study) and late plasma glucose (3 to 5 hr) was elevated. Plasma growth hormone was elevated following l-dopa and was not suppressed by either oral or iv glucose. The studies indicate that l-dopa causes an alteration in the response to oral glucose, and a stimulation of growth hormone secretion. The control studies in the Parkinsonian patients indicated that impaired growth hormone release from insulin-induced hypoglycemia (44% of patients) and abnormal iv glucose tolerance (50% of patients) may be associated with the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Insulin and neurodegenerative disease: shared and specific mechanisms
Craft, S., & Stennis Watson, G. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00681-7 · Cited by 830
Metabolism and possible health effects of aluminum.
Ganrot, P. O. (1986) · Environmental Health Perspectives · doi:10.1289/ehp.8665363 · Cited by 483
Parkinson's disease, insulin resistance and novel agents of neuroprotection
Aviles-Olmos, I., Limousin, P., Lees, A., & Foltynie, T. (2013) · Brain · doi:10.1093/brain/aws009 · Cited by 283
Neurodegeneration in an animal model of Parkinson’s disease is exacerbated by a high-fat diet
Morris, J. K., Bomhoff, G. L., Stanford, J. A., & Geiger, P. C. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00449.2010 · Cited by 163
Calsolaro, V., & Edison, P. (2015) · CNS Drugs · doi:10.1007/s40263-015-0301-8 · Cited by 93
Metadata
- Authors
- BOYD, A. E., LEBOVITZ, H. E., & FELDMAN, J. M.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1971-11
- Volume
- 33
- Issue
- 5
- Pages
- 829-837
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2020104218
- Cited by
- 84
- References
- 0
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endocrine Function and Glucose Metabolism in Patients with Parkinson's Disease and their Alteration by l-Dopa1. https://app.cochat.ai/papers/10.1210/jcem-33-5-829
- The paper
- BOYD, A. E., LEBOVITZ, H. E., & FELDMAN, J. M. (1971). Endocrine Function and Glucose Metabolism in Patients with Parkinson's Disease and their Alteration by l-Dopa1. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jcem-33-5-829
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.